Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors

被引：0
|
作者：
Sharma, Sunil
Starodub, Alexander
Xu, Nong
Chaudhry, Arvind
Sun, Meili
Pelster, Meredith
Fu, Yinjia
Zhang, Xinyu
Huang, Zhao
Liu, Wenyu
Hsu, Karl
机构：
[1] Honor Hlth, Scottsdale, AZ USA
[2] Parkview Canc Inst, Parkview Physician Grp, Cincinnati, OH USA
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[4] Summit Canc Centers, Spokane Valley, WA USA
[5] Jinan Cent Hosp, Jinan, Peoples R China
[6] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[7] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
[8] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
[9] Zai Lab US LLC, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Clinical translation of biomarkers for ZL-1211, an anti-CLDN18.2 antibody, in patients with advanced solid tumors from a phase I dose-escalation study
    Luo, Zhen
    Wang, Xiao
    Zeng, Xuehuo
    Yi, Jiaqing
    Burns, Tegan
    Liu, Herman
    Zhang, Xinyu
    Liu, Wenyu
    Hsu, Karl
    Gong, Hua
    CANCER RESEARCH, 2023, 83 (07)
  • [3] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [4] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [7] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [8] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [10] A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors
    Huang, Zhiyu
    Xu, Yanjun
    Hong, Wei
    Gong, Lei
    Chen, Kaiyan
    Qin, Jing
    Xie, Fajun
    Wang, Feng
    Tian, Xin
    Meng, Xiangrui
    Feng, Wenlei
    Li, Lingyan
    Zhang, Baihui
    Kang, Xiaoyan
    Fan, Yun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345